-
Inaugural Global Rheumatology Summit added to ACR Convergence
Evelyn Hsieh, MD, PhD, and Eric L. Matteson, MD, MACR, of the ACR’s Global Engagement Special Committee preview the topics and experts that will be a part of the all-day summit on Nov. 3. The summit is included with the All-Access Pass.
-
Plan your daily experience at ACR Convergence
ACR Convergence 2021 will have a slightly updated schedule to maximize the educational and networking opportunities.
-
Q&A: ACR President David Karp previews ACR Convergence 2021
Dr. Karp shares highlights for the meeting, which starts Nov. 1 with early access to the virtual platform and continuing through the ACR Review Course on Nov. 10.
-
COVID-19 session reviews new pediatric condition, MIS-C
Of all the questions raised by the COVID-19 pandemic, its effect on children has been one of the most perplexing.
-
Ocular and dental experts examine Sjögren’s symptoms
Only 1 in 20 individuals with the disease report being referred for a Sjögren’s workup by their eye care provider, according to a patient survey supported by the Sjögren’s Foundation.
-
Improvements in testing, updates for care needed for antiphospholipid syndrome
There is a clear need for more, and more effective, tests for antiphospholipid syndrome. The current battery of lupus anticoagulant, anti-cardiolipin antibody, and anti-β2-glycoprotein-I is far from ideal.
-
Skin symptoms provide clues to pediatric diseases
The skin can offer clues to help make the correct diagnosis for many pediatric rheumatology diseases, and a session at ACR Convergence 2020 shared some of the most important things to look for when making a diagnosis.
-
PROs, new therapies, combined management shape modern psoriatic arthritis treatment
Traditionally used in research, patient-reported outcomes have expanded into healthcare quality evaluations as well as clinical practice since being introduced to rheumatology in the 1980s.
-
Lung inflammation could be the genetic disorder COPA syndrome, not rheumatic disease
COPA syndrome is a dysfunction of lung epithelial cells producing surfactant that is virtually indistinguishable from a variety of rheumatic diseases on initial examination.
-
FDA update session includes information about immunomodulators for treating COVID-19
A better understanding of COVID-19’s pathogenesis, manifestations, natural history, and immunopathology will bring more safe and effective therapies.